Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3K delta Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共2页
• 作者

  Qi Junyuan; Song Yuqin; Jiang Bo; Li Jianyong; Tu Meifeng; Ping Lingyan; Li Zengjun; Xu Wei; Zhu Huayuan; Zhu Jun; Bao Hanying; Xu Zusheng; Qiu Lugui;

  展开▼
• 作者单位

  Chinese Acad Med Sci Inst Hematol Tianjin Peoples R China;

  Peking Univ Canc Hosp &

  Inst Dept Lymphoma Key Lab Carcinogenesis &

  Translat Res Minist Educ;

  Chinese Acad Med Sci Inst Hematol Tianjin Peoples R China;

  Nanjing Med Univ Jiangsu Prov Hosp Dept Hematol Affiliated Hosp 1 Nanjing Jiangsu Peoples R;

  Peking Univ Canc Hosp &

  Inst Dept Lymphoma Beijing Peoples R China;

  Peking Univ Canc Hosp &

  Inst Dept Lymphoma Key Lab Carcinogenesis &

  Translat Res Minist Educ;

  Chinese Acad Med Sci Inst Hematol Tianjin Peoples R China;

  Nanjing Med Univ Jiangsu Prov Hosp Dept Hematol Affiliated Hosp 1 Nanjing Jiangsu Peoples R;

  Nanjing Med Univ Jiangsu Prov Hosp Dept Hematol Affiliated Hosp 1 Nanjing Jiangsu Peoples R;

  Peking Univ Canc Hosp &

  Inst Dept Lymphoma Key Lab Carcinogenesis &

  Translat Res Minist Educ;

  Shanghai Yingli Pharmaceut Co Ltd Shanghai Peoples R China;

  Shanghai Yingli Pharmaceut Co Ltd Shanghai Peoples R China;

  Inst Hematol &

  Blood Dis Hosp Tianjin Peoples R China;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词